Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Genvoya tenofovir alafenamide fumarate regulatory update

November 23, 2015 8:00 AM UTC

FDA approved an NDA from Gilead for Genvoya tenofovir alafenamide fumarate/elvitegravir/cobicistat/emtricitabine from Gilead to treat HIV-1 infection in patients ages >=12. Gilead launched the drug at an annual wholesale acquisition cost (WAC) of $31,362. In September, EMA’s CHMP recommended approval of Genvoya, which is a single, once-daily tablet containing 10 mg TAF, 150 mg elvitegravir, 150 mg cobicistat and 200 mg emtricitabine. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article